炎症性肠病患者因呼吸道合胞病毒住院风险增加
本研究基于TriNetX多机构研究网络开展回顾性队列研究,比较IBD合并RSV感染患者与非IBD RSV感染患者的住院风险。经1:1倾向评分匹配后,IBD-RSV队列住院风险显著升高(aOR 1.30,95%CI 1.06-1.59),但复合并发症结局无差异;近期使用全身性糖皮质激素与住院风险升高相关(aOR 1.86,95%CI 1.30-2.59)。
要点
- IBD合并RSV感染患者住院风险较非IBD患者升高30%(aOR 1.30)。
- 近期3个月内使用全身性糖皮质激素使IBD-RSV患者住院风险升高86%。
- IBD-RSV患者可能受益于推荐用于60岁以上成人的新型RSV疫苗。
核心结论
- 成人IBD患者合并RSV感染时住院风险显著增加,且近期使用全身性糖皮质激素进一步升高该风险。
研究设计与样本
- 回顾性队列研究,使用多机构研究网络TriNetX,纳入2007年1月1日至2023年2月27日期间RSV感染的IBD患者与非IBD对照,进行1:1倾向评分匹配。
主要发现
- IBD-RSV队列794例,非IBD-RSV队列93,074例;IBD-RSV队列平均年龄55.6±20岁,女性占59%,白人占80%,克罗恩病占56.9%。
- IBD-RSV队列住院风险升高(aOR 1.30,95%CI 1.06-1.59)。
- 两组住院相关并发症复合结局风险无差异(aOR 0.83,95%CI 0.58-1.19)。
- IBD-RSV队列中近期(<3个月)全身性糖皮质激素使用与住院风险升高相关(aOR 1.86,95%CI 1.30-2.59)。
临床怎么用
- 对IBD患者应重视RSV感染的预防,尤其是近期使用全身性糖皮质激素者。
- IBD合并RSV感染患者可能受益于推荐用于60岁以上成人的新型RSV疫苗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with inflammatory bowel disease (IBD) are at increased risk of developing respiratory infections. Respiratory syncytial virus (RSV) is a common respiratory virus with adverse outcomes in older adults. This study aimed to determine whether patients with IBD are at increased risk of a serious infection due to RSV. METHODS: We conducted a retrospective study using the multi-institutional research network TriNetX to assess the risk of hospitalization in a cohort of patients with IBD compared with that in a non-IBD control cohort with RSV infection from January 1, 2007, to February 27, 2023. One-to-one (1:1) propensity score matching was performed for demographic variables and RSV risk factors between the 2 cohorts. Risk was expressed as adjusted odds ratio (aOR) with 95% confidence interval (CI). RESULTS: There were 794 patients in the IBD-RSV cohort and 93,074 patients in the non-IBD-RSV cohort. The mean age of the IBD-RSV cohort was 55.6 ± 20 years, 59% were female, 80% were White, and 56.9% had Crohn's disease. The IBD-RSV cohort was at an increased risk of hospitalization (aOR 1.30, 95% CI 1.06-1.59). There was no difference in the risk (aOR 0.83, 95% CI 0.58-1.19) of a composite outcome of hospitalization-related complications between the 2 cohorts. Recent systemic corticosteroid use (<3 months) was associated with an increased risk of hospitalization (aOR 1.86, 95% CI 1.30-2.59) in the IBD-RSV cohort. DISCUSSION: We found that adult patients with IBD and RSV infection are at an increased risk of hospitalization and may benefit from the new RSV vaccine recommended for adults aged 60 years and older.
引用
- Smith RA, Desai A, Barnes EL, et al. Patients With Inflammatory Bowel Disease Are at Increased Risk of Hospitalization Due to Respiratory Syncytial Virus. Am J Gastroenterol. 2024. PMID: 38318981. doi:10.14309/ajg.0000000000002682
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。